About Heparin
Heparin is an anticoagulant or blood thinner produced by basophils and mast cells. Though it has no effect on already formed clots, it enables the body's natural clot
lysis mechanisms to function and dissolve clots. A porcine intestine or bovine lungs extract of heparin is used pharmaceutically in conditions such as DVT, pulmonary
embolism, acute coronary syndrome, and atrial fibrillation to prevent clots. It is also used during surgeries to prevent clot formation.
Technavio's analysts forecast the global heparin market to grow at a CAGR of -4.80% over the period 2014-2019.
Covered in this Report
This report covers the present scenario and the growth prospects of the global heparin market for the period 2015-2019. To calculate the market size, the report
considers revenue generated from the sales of generic and branded therapeutic products, including
• Unfractionated heparin (UFH)
• Low molecular weight heparin (LMWH)
• Ultra low molecular weight heparin (ULMWH)
Technavio's report, Global Heparin Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the
market landscape and its growth prospects in the coming years. The report also includes the discussion of the key vendors operating in this market.
Key Regions
• Americas
• APAC
• EMEA
Key Vendors
• Aspen
• Leo Pharma
• Pfizer
• Sanofi-Aventis
Other Prominent Vendors
• Alchemia
• Archimedes Pharma
• Celgene
• Dr. Reddy's
• Eisai
• Laboratorios Rovi Pharmaceuticals
• Lee's Pharmaceutical
• Menarini Group
• Mylan
• Sagent Pharmaceuticals
• Fresenius Kabi
• GlaxoSmithKline
• Hospira
• Sigma Tau
• UCB
Market Driver
• Increasing Prevalence of Diseases
• For a full, detailed list, view our report
Market Challenge
• Generic Drug Use
• For a full, detailed list, view our report
Market Trend
• Expected Exploitation of New Therapeutic Use
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Product Profiles
05.1.1 Arixtra
05.1.2 Fraxiparine
05.1.3 Innohep
05.1.4 Fragmin
05.1.5 LovenoxClexane
06. Introduction
07. Mechanism of Action
07.1 Mechanism of Action
07.2 Pharmacology of UFH
07.3 Pharmacology of LMWH
08. Clinical Uses of Heparin
08.1 DVT
08.2 Pulmonary Embolism
08.3 Acute Coronary Syndrome
08.4 Atrial Fibrillation
08.5 Hemodialysis
08.6 Coronary Angioplasty
09. Limitations of Heparin Use
09.1 Pharmacokinetic Limitations
09.2 Biophysical Limitations
09.3 Biological Limitations
10. Suppliers of Crude Heparin
10.1 FDA Guidance for Heparin Suppliers
11. Market Landscape
11.1 Market Overview
11.2 Market Size and Forecast
11.3 Five Forces Analysis
12. Market Segmentation by Product Type
12.1 UFH
12.2 LMWH
12.2.1 Deaminative Cleavage with Nitrous Acid or Organic Nitrite
12.2.2 Chemical or Enzymatic Beta Elimination
12.2.3 Oxidative Depolymerization
12.3 ULMWH
13. Market Segmentation by Route of Administration
13.1 IV InjectionInfusion
13.2 SC Injection
14. Geographical Segmentation
14.1 Global Heparin Market by Geographical Segmentation 2014-2019
15. Buying Criteria
16. Market Growth Drivers
17. Drivers and Their Impact
18. Market Challenges
19. Impact of Drivers and Challenges
20. Market Trends
21. Trends and Their Impact
22. Vendor Landscape
22.1 Competitive Scenario
22.1.1 Key News
22.1.2 Mergers and Acquisitions
22.2 Market Share Research 2014
22.2.1 Sanofi
22.2.2 Pfizer
22.2.3 Aspen Pharma
22.2.4 LEO Pharma
22.3 Other and Future Prominent Vendors
23. Key Takeaways of Global Heparin Market
24. Key Vendor Research
24.1 Aspen
24.1.1 Key Facts
24.1.2 Business Overview
24.1.3 Business Segmentation by Revenue 2014
24.1.4 Geographical Segmentation by Revenue 2014
24.1.5 Business Strategy
24.1.6 Recent Developments
24.1.7 SWOT Analysis
24.2 LEO Pharma
24.2.1 Key Facts
24.2.2 Business Description
24.2.3 Business Segmentation
24.2.4 Revenue Comparison by Business Segmentation 2011-2013
24.2.5 Revenue by Geographical Segmentation
24.2.6 Business Strategy
24.2.7 Key Developments
24.2.8 SWOT Analysis
24.3 Pfizer
24.3.1 Key Facts
24.3.2 Business Overview
24.3.3 Business Segmentation by Revenue 2014
24.3.4 Business Segmentation by Revenue 2013 and 2014
24.3.5 Geographical Segmentation by Revenue 2014
24.3.6 Business Strategy
24.3.7 Key Developments
24.3.8 SWOT Analysis
24.4 Sanofi
24.4.1 Key Facts
24.4.2 Business Description
24.4.3 Business Segmentation
24.4.4 Revenue by Business Segmentation
24.4.5 Revenue Comparison 2012 and 2013
24.4.6 Sales by Geography
24.4.7 Business Strategy
24.4.8 Key Developments
24.4.9 SWOT Analysis
25. Other Reports in This Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Process of Blood Coagulation
Exhibit 3: Mechanism of Action
Exhibit 4: Process of Crude Heparin Production in China
Exhibit 5: Global Heparin Market 2014-2019 ($ billions)
Exhibit 6: Segmentation of Global Heparin Market by Product Type
Exhibit 7: Segmentation of Global Heparin Market by Route of Administration
Exhibit 8: Segmentation of Global Heparin Market by Geography 2014
Exhibit 9: Global Heparin Market Share 2014
Exhibit 10: Lovenox: YoY Growth Rate and Revenue 2010-2014 ($ millions)
Exhibit 11: Lovenox: Region-Wise Revenue Comparison 2010-2014 ($ millions)
Exhibit 12: Fragmin: YoY Growth Rate and Revenue 2010-2014 ($ millions)
Exhibit 13: Fragmin: Region-Wise Revenue Comparison 2012-2013 ($ millions)
Exhibit 14: Arixtra: YoY Growth Rate and Revenue of 2010-2013 ($ millions)
Exhibit 15: Arixtra: Region-Wise Revenue Comparison 2010-2013 ($ millions)
Exhibit 16: Fraxiparine: YoY Growth Rate and Revenue 2010-2013 ($ millions)
Exhibit 17: Fraxiparine: Region-Wise Revenue Comparison 2010-2013 ($ millions)
Exhibit 18: Key Takeaways of Heparin Market
Exhibit 19: Aspen: Business Segmentation by Revenue 2014 ($ millions)
Exhibit 20: Aspen: Geographical Segmentation by Revenue 2014
Exhibit 21: LEO Pharma: Business Segmentation
Exhibit 22: LEO Pharma: Revenue Comparison by Business Segmentation 2011-2013 ($ billions)
Exhibit 23: LEO Pharma: Revenue by Geographical Segmentation 2013
Exhibit 24: Pfizer: Business Segmentation by Revenue 2014
Exhibit 25: Pfizer: Business Segmentation by Revenue 2013 and 2014 ($ billions)
Exhibit 26: Pfizer: Geographical Segmentation by Revenue 2014
Exhibit 27: Sanofi: Business Segmentation
Exhibit 28: Sanofi: Revenue by Business Segmentation 2013
Exhibit 29: Sanofi: Revenue by Business Segmentation 2012 and 2013 ($ millions)
Exhibit 30: Sanofi: Sales Revenue by Geographical Segmentation 2013
